en · de · es · fr · pt
faq-desk.peptides6155.com › News › Sr9009 Identity And Mechanism — Common Mistakes

Sr9009 Identity And Mechanism — Common Mistakes

By Editorial Desk · published 2025-11-23 · last reviewed 2026-01-07 · News

This is a working overview of circadian clock, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-01-07. Anything still debated is marked as such rather than presented as settled.

SR9009 Identity and Mechanism

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

Background and Receptor Mechanism

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also marketed informally as Stenabolic
Chemical classSynthetic REV-ERB agonistBinds REV-ERBα and REV-ERBβ
Molecular formulaC24H30ClN3O4SApproximate molecular weight 492 g/mol
CAS Registry Number1379686-30-2Identifier for the parent compound
Regulatory statusNot approved for human useProhibited in sport by WADA

Background and Research Status

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

Related pages on this site

Identity, Handling, and Regulation

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Notes from published material

Prior to this, there had been failed synthesis attempts in 1986–87 at the Joint Institute for Nuclear Research in Dubna (then in the Soviet Union) and in 1990 at the GSI. A 1995 attempt at the Lawrence Berkeley National Laboratory resulted in signs suggesting but not pointing conclusively at the discovery of a new isotope 267Ds formed in the bombardment of 209Bi with 59Co, and a similarly inconclusive 1994 attempt at the JINR showed signs of 273Ds being produced from 244Pu and 34S. Each team proposed its own name for element 110: the American team proposed hahnium after Otto Hahn in an attempt to resolve the controversy of naming element 105 (which they had long been suggesting this name for), the Russian team proposed becquerelium after Henri Becquerel, and the German team proposed darmstadtium after Darmstadt, the location of their institute. The IUPAC/IUPAP Joint Working Party (JWP) recognised the GSI team as discoverers in their 2001 report, giving them the right to suggest a name for the element.

Hans Charles Freeman AM, FAA (26 May 1929 – 9 November 2008) was a German-born Australian bioinorganic chemist, protein crystallographer, and professor of inorganic chemistry who spent most of his academic career at the University of Sydney. His best known contributions to chemistry were his work explaining the unusual structural, electrochemical, and spectroscopic properties of blue copper proteins, particularly plastocyanin. He also introduced protein crystallography to Australia and was a strong advocate for courses to ensure Australian scientists have good access to "big science" facilities. Freeman has received numerous honours, including being elected a Fellow of the Australian Academy of Science (FAA) and appointed a Member of the Order of Australia (AM) by the Australian Government. He was a charismatic lecturer who voluntarily continued teaching well into his formal retirement and imbued his students with a love of science.

Singapore consists of over 60 islands, including the main island, also known as Pulau Ujong. There are two man-made connections to Johor, Malaysia: the Johor–Singapore Causeway in the north and the Tuas Second Link in the west. Jurong Island, Pulau Tekong, Pulau Ubin and Sentosa Island are the largest of Singapore's smaller islands. The highest natural point is Bukit Timah Hill at 163.63 m (537 ft). Under British rule, Christmas Island, the Cocos (Keeling) Islands, and Labuan were administered from Singapore. Labuan was under this arrangement from 1907 until it was eventually merged into the Crown Colony of North Borneo in 1948. Shortly before Singapore achieved full internal self-governance in 1959, both Christmas Island and the Cocos (Keeling) Islands were transferred to Australia in 1958. Today, Pedra Branca at the South China Sea is the nation's easternmost point. Land reclamation projects have increased Singapore's land area from roughly 580 km2 (220 sq mi) in the 1960s to 770 km2 (300 sq mi) by the 2030s, an increase of over 30% or 190 km2 (73 sq mi). Some projects involve merging smaller islands to form larger and more functional landmasses, as was the case with Jurong Island. The type of sand used in reclamation works is found in rivers and beaches rather than deserts and remains in great demand worldwide. As such, neighbouring Southeast Asian countries have either restricted or barred sand exports to Singapore since the 2010s.

== Pro-Soviet accounts == Soviet historiography on the Cold War era was overwhelmingly dictated by the Soviet state, and blamed the West for the Cold War. In Britain, the historian E. H. Carr wrote a 14-volume history of the Soviet Union, which was focused on the 1920s and published 1950–1978. His friend R. W. Davies said Carr belonged to the anti-Cold War school of history, which regarded the Soviet Union as the major progressive force in the world, the United States as the world's principal obstacle to the advancement of humanity and the Cold War as a case of American aggression against the Soviet Union. Carr criticized those Anglophone historians, who he felt had unfairly judged the Soviet Union by the cultural norms of Britain and the United States.

Sources: en.wikipedia.org

Further detail

According to Thomson's model, all of the alpha particles should have passed through with negligible deflection. Rutherford deduced that the positive charge of the atom is not distributed throughout the atom's volume as Thomson believed, but is concentrated in a tiny nucleus at the center. This nucleus also carries most of the atom's mass. Only such an intense concentration of charge, anchored by its high mass, could produce an electric field strong enough to deflect the alpha particles as observed. Rutherford's model, being supported primarily by scattering data unfamiliar to many scientists, did not catch on until Niels Bohr joined Rutherford's lab and developed a new model for the electrons. Rutherford model predicted that the scattering of alpha particles would be proportional to the square of the atomic charge. Geiger and Marsden's based their analysis on setting the charge to half of the atomic weight of the foil's material (gold, aluminium, etc.). Amateur physicist Antonius van den Broek noted that there was a more precise relation between the charge and the element's numeric sequence in the order of atomic weights. The sequence number came be called the atomic number and it replaced atomic weight in organizing the periodic table.

==== Human rights violations at Abu Ghraib and Haditha ==== Hitchens criticised human rights abuses by US forces in Iraq but argued that conditions had improved considerably compared either to Saddam Hussein's previous regime or to previous US military actions in Vietnam. In 2005, Hitchens criticised the abuse of prisoners in Abu Ghraib but argued that overall "prison conditions at Abu Ghraib have improved markedly and dramatically since the arrival of Coalition troops in Baghdad", arguing that "before March 2003, Abu Ghraib was an abattoir, a torture chamber, and a concentration camp." In a 5 June 2006 article on the alleged killings of Iraqi civilians by U.S. Marines in Haditha, Hitchens argued that whether or not a massacre had taken place, comparisons with the My Lai massacre in Vietnam were "so much propaganda and hot air" that ignored substantial changes in the rules of engagement and US Army procedures and training designed to prevent and discourage such an event. He argued that lesson had been learned such that "as a consequence, a training film about My Lai – "if anything like this happens, you have really, truly screwed up" – has been in use for U. S. soldiers for some time".

== Program structure == Laboratory stewardship programs commonly include four components: governance, interventions, data extraction and monitoring, and review of data coupled with strategies for improvement. Governance generally involves institutional leadership, multidisciplinary committees, laboratory expertise, and support from clinical, quality-improvement, financial, and information-technology personnel. Programs may also establish systems to support the appropriate financial coverage of medically necessary laboratory testing. Data extraction and monitoring can be used to identify patterns of laboratory test utilization, including potential overuse or underuse, and to monitor the effects of stewardship interventions. Monitoring may include test volumes, ordering patterns, costs, the appropriateness of test orders, retrieval of results, and interpretation of results. The resulting data can be reviewed to prioritize opportunities for improvement and guide the selection or modification of stewardship strategies. The design of stewardship programs and their interventions can vary according to institutional priorities, available resources, and clinical setting. Implementation science can be used to identify behavioral and organizational factors that influence laboratory test use and to select interventions appropriate to those factors.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.

Is SR9009 approved for human use?

No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.

Why is SR9009 banned in sport?

The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Network